Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EXELIXIS, INC.

(EXEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société EXELIXIS, INC.
01/18Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapie..
BU
01/10EXELIXIS : Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Prov..
PU
01/10EXELIXIS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
01/09Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Pro..
BU
01/06Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antib..
BU
01/05Exelixis Appoints Vicki L. Goodman, M.D., as Executive Vice President, Product Developm..
AQ
01/05Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozan..
BU
01/04Exelixis to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference on Jan..
BU
01/04Exelixis Appoints Vicki L. Goodman, M.D., as Executive Vice President, Product Developm..
BU
2021Exelixis Elects Jacqueline Wright to Its Board of Directors
AQ
2021EXELIXIS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2021Exelixis Elects Jacqueline Wright to Its Board of Directors
BU
2021Exelixis Announces Initiation of Phase 1b Trial Evaluating XL092 in Combination with Im..
BU
2021Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantin..
AQ
2021Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantin..
BU
2021Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozan..
BU
2021Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November ..
BU
2021EXELIXIS : Q3 Earnings Snapshot
AQ
2021Exelixis Q3 Earnings Slides With Appendix
PU
2021EXELIXIS ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE -..
PU
2021Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate Update
BU
2021EXELIXIS : to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
BU
2021EXELIXIS : In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance ..
AQ
2021EXELIXIS : In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance ..
BU
2021EXELIXIS : and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement..
BU
2021EXELIXIS : Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in ..
BU
2021EXELIXIS : Announces U.S. FDA Approval of CABOMETYX (cabozantinib) for Patients with Previ..
AQ
2021EXELIXIS : Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patien..
AQ
2021EXELIXIS : Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patien..
BU
2021EXELIXIS : Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Prev..
BU
2021EXELIXIS : Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Reg..
BU
2021EXELIXIS : Statement on the Passing of Two Senior Executives
BU
2021EXELIXIS : to Webcast Fireside Chats as Part of Virtual Investor Conferences in September
BU
2021Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX (cabo..
AQ
2021EXELIXIS : Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabo..
BU
2021EXELIXIS : and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Onc..
BU
2021EXELIXIS : Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Applic..
AQ
2021EXELIXIS : Q2 Earnings Snapshot
AQ
2021EXELIXIS : Announces Second Quarter 2021 Financial Results and Provides Corporate Update
BU
2021EXELIXIS : Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Applic..
BU
2021EXELIXIS : to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021
BU
2021EXELIXIS : William Blair Biotech Focus Conference Presentation
PU
2021EXELIXIS : to Present at the Virtual William Blair Biotech Focus Conference on July 15, 20..
BU
2021Etsy, Intellia rise; Carnival, Exelixis fall
AQ
2021EXELIXIS : and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibi..
BU
2021EXELIXIS, INC. : Other Events (form 8-K)
AQ
2021EXELIXIS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2021EXELIXIS : Chief Medical Officer Gisela M. Schwab, M.D., to Take Medical Leave of Absence
AQ
2021EXELIXIS : Chief Medical Officer Gisela M. Schwab, M.D., to Take Medical Leave of Absence
BU
2021EXELIXIS : Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers ..
BU
2021EXELIXIS : and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Ca..
BU
2021EXELIXIS : Announces Positive Phase 2 Results for CABOMETYX (cabozantinib) in Combination ..
AQ
2021EXELIXIS : Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9..
AQ
2021Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis of Phase ..
AQ
2021EXELIXIS : Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis of Phase 3..
BU
2021EXELIXIS : Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9..
BU
2021EXELIXIS : Announces Positive Phase 2 Results for CABOMETYX® (cabozantinib) in Combination..
BU
2021EXELIXIS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
2021EXELIXIS : to Webcast Fireside Chats as Part of Virtual Investor Conferences in June
BU
2021EXELIXIS : Announces Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with M..
BU
2021IPSEN : opts-in to join Exelixis with ongoing development of Cabometyx for people living w..
AQ
2021EXELIXIS, INC. : Other Events (form 8-K)
AQ
2021EXELIXIS : Q1 Earnings Snapshot
AQ
2021EXELIXIS : Q1 2021 Earnings Slides With Appendix
PU
2021EXELIXIS : Announces First Quarter 2021 Financial Results and Provides Corporate Update
BU
2021EXELIXIS : Expands its Biotherapeutics Portfolio with Acquisition of GamaMabs Pharma's Fir..
AQ
2021EXELIXIS : Expands its Biotherapeutics Portfolio with Acquisition of GamaMabs Pharma's Fir..
BU
2021EXELIXIS : to Webcast Fireside Chats as Part of Virtual Investor Conferences in May
BU
2021EXELIXIS : to Release First Quarter 2021 Financial Results on Thursday, May 6, 2021
BU
2021EXELIXIS : Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Pa..
BU
2021EXELIXIS' : Partner Ipsen Receives European Commission Approval for CABOMETYX (cabozantini..
AQ
2021EXELIXIS : Announces Enrollment Completion in Phase 3 COSMIC-313 Pivotal Trial of Cabozant..
AQ
2021EXELIXIS : rsquo; Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabo..
BU
2021EXELIXIS : Announces Enrollment Completion in Phase 3 COSMIC-313 Pivotal Trial of Cabozant..
BU
2021EXELIXIS : Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Da..
BU
1  2  3  4  5  6  7  8  9Next
Upcoming event on EXELIXIS, INC.
02/17/22